Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Abstract Background A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Cancer Communications |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-019-0375-7 |
id |
doaj-6129f5be80104cb281fcc3c9e6701361 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ji-Yeon Kim Seri Park Seock-Ah Im Sung-Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young-Hyuck Im Tae-Yong Kim Kyung-Hun Lee Jin-Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group |
spellingShingle |
Ji-Yeon Kim Seri Park Seock-Ah Im Sung-Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young-Hyuck Im Tae-Yong Kim Kyung-Hun Lee Jin-Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) Cancer Communications Metastatic breast cancer Eribulin Paclitaxel Neuropathy Quality of life Functional assessment of cancer therapy-taxane questionnaires |
author_facet |
Ji-Yeon Kim Seri Park Seock-Ah Im Sung-Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young-Hyuck Im Tae-Yong Kim Kyung-Hun Lee Jin-Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group |
author_sort |
Ji-Yeon Kim |
title |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) |
title_short |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) |
title_full |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) |
title_fullStr |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) |
title_full_unstemmed |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) |
title_sort |
quality of life outcomes including neuropathy-associated scale from a phase ii, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for her2-negative metastatic breast cancer: korean cancer study group trial (kcsg br13-11) |
publisher |
Wiley |
series |
Cancer Communications |
issn |
2523-3548 |
publishDate |
2019-05-01 |
description |
Abstract Background A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). Methods QoL was assessed using the Korean version of the FACT-Taxane questionnaires. After baseline assessment, QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to evaluate the difference in QoL between the EG and PG arms. Results Of the 118 enrolled patients, 117 responded to the FACT-Taxane questionnaires at baseline, 1 in the PG arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale scores were significantly higher in the PG arm than in the EG arm after 2–13 cycles of chemotherapy (all P < 0.05), except for the 11th cycle. Neuropathy-specific analysis showed that patients in the PG arm had earlier and more severe neuropathic symptoms than those in the EG arm (P < 0.001). Conclusions In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC. |
topic |
Metastatic breast cancer Eribulin Paclitaxel Neuropathy Quality of life Functional assessment of cancer therapy-taxane questionnaires |
url |
http://link.springer.com/article/10.1186/s40880-019-0375-7 |
work_keys_str_mv |
AT jiyeonkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT seripark qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT seockahim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT sungbaekim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT joohyuksohn qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT keunseoklee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT yeesoochae qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT kihyeonglee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT jeehyunkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT younghyuckim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT taeyongkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT kyunghunlee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT jinheeahn qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT gunminkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT inhaepark qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT soojunglee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT hyesookhan qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT sehyunkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT kyunghaejung qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT yeonheepark qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 AT koreancancerstudygroup qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311 |
_version_ |
1724863179904778240 |
spelling |
doaj-6129f5be80104cb281fcc3c9e67013612020-11-25T02:22:08ZengWileyCancer Communications2523-35482019-05-013911810.1186/s40880-019-0375-7Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)Ji-Yeon Kim0Seri Park1Seock-Ah Im2Sung-Bae Kim3Joohyuk Sohn4Keun Seok Lee5Yee Soo Chae6Ki Hyeong Lee7Jee Hyun Kim8Young-Hyuck Im9Tae-Yong Kim10Kyung-Hun Lee11Jin-Hee Ahn12Gun Min Kim13In Hae Park14Soo Jung Lee15Hye Sook Han16Se Hyun Kim17Kyung Hae Jung18Yeon Hee Park19Korean Cancer Study GroupDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan UniversityDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National UniversityDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of MedicineCenter for Breast Cancer, National Cancer CenterDepartment of Internal Medicine, Kyungpook National University HospitalDeparment of Internal Medicine, Chungbuk National University HospitalDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National UniversityDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National UniversityDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of MedicineCenter for Breast Cancer, National Cancer CenterDepartment of Internal Medicine, Kyungpook National University HospitalDeparment of Internal Medicine, Chungbuk National University HospitalDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineAbstract Background A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). Methods QoL was assessed using the Korean version of the FACT-Taxane questionnaires. After baseline assessment, QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to evaluate the difference in QoL between the EG and PG arms. Results Of the 118 enrolled patients, 117 responded to the FACT-Taxane questionnaires at baseline, 1 in the PG arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale scores were significantly higher in the PG arm than in the EG arm after 2–13 cycles of chemotherapy (all P < 0.05), except for the 11th cycle. Neuropathy-specific analysis showed that patients in the PG arm had earlier and more severe neuropathic symptoms than those in the EG arm (P < 0.001). Conclusions In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC.http://link.springer.com/article/10.1186/s40880-019-0375-7Metastatic breast cancerEribulinPaclitaxelNeuropathyQuality of lifeFunctional assessment of cancer therapy-taxane questionnaires |